Headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a news impact score of 0.23 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.9909457642537 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern’s scoring:
Spectrum Pharmaceuticals (SPPI) opened at $20.41 on Tuesday. The firm has a market cap of $2,050.00, a PE ratio of -20.41 and a beta of 1.64. The company has a current ratio of 5.04, a quick ratio of 4.89 and a debt-to-equity ratio of 0.33. Spectrum Pharmaceuticals has a 1 year low of $5.14 and a 1 year high of $23.50.
Several analysts have recently issued reports on SPPI shares. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price (up previously from $20.00) on shares of Spectrum Pharmaceuticals in a research note on Wednesday, October 18th. Jefferies Group upped their target price on shares of Spectrum Pharmaceuticals to $25.00 and gave the stock a “buy” rating in a research note on Friday, October 20th. Guggenheim started coverage on shares of Spectrum Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $32.00 target price for the company. B. Riley started coverage on shares of Spectrum Pharmaceuticals in a research note on Monday, December 18th. They issued a “buy” rating and a $26.00 target price for the company. Finally, Zacks Investment Research lowered shares of Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $22.83.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Spectrum Pharmaceuticals (SPPI) Share Price” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/13/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-spectrum-pharmaceuticals-sppi-share-price.html.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.